hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06285760 id: 135/23 briefTitle: Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure (SANDI STUDY) acronym: SANDI overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-02 date: 2025-02 date: 2024-02-29 date: 2024-03-04 name: Puerta de Hierro University Hospital class: OTHER name: Hospital Clinic of Barcelona name: Hospital Central de la Defensa Gómez Ulla name: Hospital Vall d'Hebron name: Hospital Universitario Ramon y Cajal name: University Hospital of Girona Dr.Josep Trueta name: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa briefSummary: The goal of this observational study is to assess the natriuretic effect of intravenous acetazolamide in patients admitted with heart failure and persistent congestion despite treatment with intravenous furosemide and sodium-glucose cotransporter type 2 (iSGLT2) inhibitors.
The main question it aims to answer is whether there is a difference in natriuresis 48 hours after acetazolamide association to medical treatment recommended by the guidelines (furosemide and ISGLT2). conditions: Heart Failure conditions: Persistent Congestion studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 64 type: ESTIMATED name: Standarized diuretic therapy measure: Change in natriuresis 48 hours after acetazolamide measure: Increase in diuresis 48 hours after acetazolamide administration measure: Weight difference 48 hours after acetazolamide administration measure: Difference in congestion score 48 hours after acetazolamide administration. measure: Difference in ultrasound measurements 48 hours after acetazolamide administration. measure: Changes in renal function 48 hours after acetazolamide administration. measure: Ionic (potassium (mmol/L) changes measure: chloride (mmol/L) changes 48 hours after acetazolamide administration measure: bicarbonate (mmol/L) changes 48 hours after acetazolamide administration measure: Changes in blood pressure 48 hours after administration of acetazolamide sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Julia González González city: Madrid zip: 28222 country: Spain name: Julia González González role: CONTACT phone: 0034617453693 email: juliagfk@gmail.com lat: 40.4165 lon: -3.70256 hasResults: False
nctId: NCT06285747 id: 23-004117 id: NCI-2024-01191 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 23-004117 type: OTHER domain: Mayo Clinic Institutional Review Board briefTitle: A Correlational Study: Breast Cancer-related Chest Wall Lymphedema, Quality of Life, and Shoulder Function overallStatus: RECRUITING date: 2023-07-28 date: 2025-08-01 date: 2025-08-01 date: 2024-02-29 date: 2024-02-29 name: Mayo Clinic class: OTHER briefSummary: This study evaluates how swelling in the chest following breast cancer treatment may affect patients' quality of life and shoulder function. conditions: Breast Carcinoma studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 85 type: ESTIMATED name: Non-Interventional Study measure: Chest wall lymphedema measure: Quality of life - Limb Lymphoedema Quality of Life (LymQOL) measure: Disability of the shoulder - Disabilities of the Arm, Shoulder and Hand (DASH) sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Rochester status: RECRUITING city: Rochester state: Minnesota zip: 55905 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Kayla A. Van Der Weerd, PT, DPT role: CONTACT phone: 507-266-8721 email: VanDerWeerd.Kayla@mayo.edu name: Kayla A. Van Der Weerd, PT, DPT role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06285734 id: KYLL-202312-049 briefTitle: Clinical Characteristics of Small Intestinal Bacterial Overgrowth in Individuals With Abdominal Distention overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-01-07 date: 2025-01-07 date: 2024-02-29 date: 2024-02-29 name: Shandong University class: OTHER name: Qilu Hospital of Shandong University (Qingdao) name: Jinan Central Hospital name: Zaozhuang Municipal Hospital name: Binzhou Medical University name: Weihai Municipal Hospital name: Central Hospital of Zibo name: Weifang People's Hospital name: Qilu hospital of Shandong University Dezhou hospital name: Qihe Xian Renmin Hospital briefSummary: Abdominal distention represents a prevalent clinical manifestation characterized by an unclear etiology and pathogenesis. This symptomatology is frequently observed in various conditions, including small intestinal bacterial overgrowth (SIBO) and abnormal orocecal transit time (OCTT). The utilization of the breath test as a non-invasive diagnostic approach has become widespread in recent years for identifying SIBO and abnormalities in OCTT. In this study, the prevalence of SIBO and OCTT irregularities in individuals presenting with abdominal distention was ascertained through the implementation of the breath test. Furthermore, the correlation between abdominal distention and SIBO/OCTT was analysed to enhance the elucidation of the underlying etiology of abdominal distention. These findings aim to offer valuable insights for refining clinical comprehension and strategies related to the diagnosis and treatment of abdominal distention. conditions: Abdominal Distention studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 402 type: ESTIMATED name: Breath test measure: Positive rate of SIBO in patients with abdominal distension measure: Positive rate of abnormal OCTT in patients with abdominal distension measure: Correlation between clinical features of patients with abdominal distension and SIBO measure: Correlation between clinical features of patients with abdominal distension and OCTT sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06285721 id: DELTES briefTitle: Delirium Treatment With Transcranial Electrical Stimulation acronym: DELTES overallStatus: NOT_YET_RECRUITING date: 2024-02-26 date: 2027-01-31 date: 2027-03-31 date: 2024-02-29 date: 2024-02-29 name: A.J.C. Slooter class: OTHER name: Radboud University Medical Center name: HagaZiekenhuis briefSummary: The goal of this clinical trial is to investigate the effectiveness of standardized and personalized transcranial alternating current stimulation (tACS) in patients with postoperative delirium. To investigate this, will perform a double-blind, randomized, sham-controlled, multicenter trial.
Electroencephalogram (EEG) will be measured directly before and directly after the first stimulation session to assess whether tACS can reduce relative delta power. tACS or sham treatment will be given once daily for a maximum of 14 days, or until resolution of delirium or discharge (whichever comes first). During the treatment phase, presence and severity of delirium will be assessed daily. After the treatment phase, an additional EEG will be measured. Cognitive status will be assessed three months postoperative. conditions: Delirium studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 159 type: ESTIMATED name: transcranial alternating current stimulation (tACS) name: Sham transcranial alternating current stimulation (tACS) measure: Relative delta power measure: Duration of delirium measure: Severity of delirium measure: Length of hospital stay measure: Cognitive status three months post delirium measure: Subjective sensations during treatment measure: Average peak frequency measure: Phase Lag Index measure: Corrected Amplitude Envelope Correlation (AECc) measure: Relative power sex: ALL minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Radboudumc city: Nijmegen state: Gelderland zip: 6525 GA country: Netherlands name: Indira Tendolkar, MD, PhD role: CONTACT lat: 51.8425 lon: 5.85278 facility: HagaZiekenhuis city: Den Haag state: Zuid-Holland zip: 2545 AA country: Netherlands name: Thomas H Ottens, MD, PhD role: CONTACT lat: 52.07667 lon: 4.29861 hasResults: False
nctId: NCT06285708 id: 2023B0193 briefTitle: Enhancing the Effectiveness of Prolonged Exposure Among Suicidal Individuals With PTSD overallStatus: RECRUITING date: 2024-02 date: 2025-07 date: 2026-01 date: 2024-02-29 date: 2024-02-29 name: Ohio State University class: OTHER briefSummary: The long-term goal of this study is to reduce suicidal thoughts and behaviors among treatment-seeking individuals who also have posttraumatic stress disorder (PTSD). Prolonged exposure (PE) and crisis response plan (CRP) have demonstrated empirical support for reducing suicide attempts as compared to treatment as usual. However, no studies to date have assessed their effectiveness when used in combination. In light of this knowledge gap, the primary objective of this study will be to test the effectiveness of PE augmented with CRP as compared to PE with care as usual (self-guided treatment plan), an active comparator, for the reduction of suicide ideations and attempts for individuals with comorbid PTSD. conditions: PTSD conditions: Suicidal Ideation conditions: Suicide, Attempted conditions: Trauma, Psychological studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Prolonged exposure measure: Beck Scale for Suicidal Ideation (SSI) measure: Self-Injurious Thoughts and Behaviors Interview-Revised (SITBI-R) measure: PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 (PCL-5) measure: Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 Self-Rated Level 1 Cross-Cutting Symptom Measure measure: Interpersonal Needs Questionnaire (INQ) - Abbreviated measure: Beck Hopelessness Scale (BHS) - Abbreviated measure: Brief Suicide Cognitions Scale (SCS) measure: Difficulties in Emotion Regulation Scale-Short Form (DERS-SF) measure: Monetary Choice Questionnaire (MCQ) measure: Behavioral Inhibition Scale (BIS) measure: Behavioral Activation Scale (BAS) measure: Patient-Reported Outcomes Measurement Information System (PROMIS) Measures measure: Patient-Reported Outcomes Measurement Information System (PROMIS) Measures measure: Patient-Reported Outcomes Measurement Information System (PROMIS) Measures measure: Patient-Reported Outcomes Measurement Information System (PROMIS) Measures measure: Patient-Reported Outcomes Measurement Information System (PROMIS) Measures measure: Patient-Reported Outcomes Measurement Information System (PROMIS) Measures measure: Patient-Reported Outcomes Measurement Information System (PROMIS) Measures sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Ohio State University status: RECRUITING city: Columbus state: Ohio zip: 43210 country: United States name: Jaryd Hiser role: CONTACT phone: 614-814-0163 email: jaryd.hiser@osumc.edu name: Justin Baker, Ph.D. role: SUB_INVESTIGATOR lat: 39.96118 lon: -82.99879 hasResults: False
nctId: NCT06285695 id: ILS241-I001 briefTitle: Clareon Toric Study (T2-T9) overallStatus: RECRUITING date: 2024-04-04 date: 2028-04 date: 2028-04 date: 2024-02-29 date: 2024-04-24 name: Alcon Research class: INDUSTRY briefSummary: The purpose of this post-market study is to describe the long-term safety and performance of Clareon Toric Intraocular Lenses (IOLs). conditions: Aphakia conditions: Corneal Astigmatism studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Clareon Toric IOL name: Cataract surgery measure: Mean monocular best corrected distance visual acuity (BCDVA) measure: Mean monocular absolute residual refractive cylinder measure: Mean absolute IOL rotation from previous visit measure: Mean absolute IOL rotation from end of surgery supine baseline to each subsequent visit sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Gimbel Eye Centre status: RECRUITING city: Calgary state: Alberta zip: T3B 0M3 country: Canada lat: 51.05011 lon: -114.08529 facility: Uptown Eye Specialists status: RECRUITING city: Concord state: Ontario zip: L4K 2Z5 country: Canada lat: 43.80011 lon: -79.48291 facility: Prism Eye Institute status: RECRUITING city: Oakville state: Ontario zip: L6H 0J8 country: Canada lat: 43.45011 lon: -79.68292 facility: Laurentians Eye Institute status: RECRUITING city: Boisbriand state: Quebec zip: J7H 0E8 country: Canada lat: 45.61678 lon: -73.83249 facility: Bellevue status: RECRUITING city: Montréal state: Quebec zip: H1V 1G5 country: Canada lat: 45.50884 lon: -73.58781 facility: McGill University status: RECRUITING city: Montréal state: Quebec zip: R7A 3N2 country: Canada lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06285682 id: ETH2324-2826 briefTitle: Bioavailability of Hydroxytyrosol in Healthy Adult Humans overallStatus: ACTIVE_NOT_RECRUITING date: 2024-02-03 date: 2024-03-30 date: 2024-05-01 date: 2024-02-29 date: 2024-02-29 name: Anglia Ruskin University class: OTHER name: Fattoria La Vialla name: Instituto Kurz briefSummary: Brief summary: There is current scientific interest in hydroxytyrosol due to its anti-inflammatory and antioxidant properties, efficient protection of vascular tissue and ability to neutralise free radicals via hydrogen donation. Recognised as the potent polyphenol within a commercially available olive-fruit water (OliPhenolia®), data from this research will determine the dose of OliPhenolia® required for the optimum absorption and metabolism of hydroxytyrosol. The primary aim of this research is to identify the dose of hydroxytyrosol (0.5, 1.0 or 1.5 mg∙kg-1) within OliPhenolia® that demonstrates the greatest area under the plasma concentration curve for hydroxytyrosol over a four-hour period. A secondary aim is to assess maximum concentration (CMAX) and time to maximum concentration (TMAX) of total hydroxytyrosol and secondary metabolites (Tyrosol, HT-3-glucoronide, HT-3-sulphate, 3,4-Dihydroxyphenylacetic Acid, Homovanillic Acid and Oleuropein) following consumption of 3 randomised doses of OliPhenolia® on separate occasions with healthy adult volunteers. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Participants are randomly assigned a dose of olive-derived hydroxytyrosol in a double-blind manner. Following a ≥3 day wash out participants then cross-over to an alternate dose. This process is then repeated for the third and final dose. primaryPurpose: BASIC_SCIENCE masking: DOUBLE maskingDescription: Volume of nutritional supplement is provided in a double-blinded manner. Both participants and research testers will be masked from knowing the specifics of the volume allocation. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 8 type: ACTUAL name: OliPhenolia®) measure: Hydroxytyrosol bioavailability measure: Bioavailability of hydroxytyrosol metabolites. measure: Hydroxytyrosol CMax measure: Hydroxytyrosol TMAX measure: CMAX of hydroxytyrosol secondary metabolites measure: TMAX of hydroxytyrosol secondary metabolites sex: ALL minimumAge: 21 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University city: Cambridge zip: CB5 8DZ country: United Kingdom lat: 52.2 lon: 0.11667 hasResults: False
nctId: NCT06285669 id: KA18/35 briefTitle: Effects of Kinesiotaping on Respiratory Muscles in Very Preterm Infants overallStatus: COMPLETED date: 2018-01-01 date: 2020-06-30 date: 2020-06-30 date: 2024-02-29 date: 2024-02-29 name: Ondokuz Mayıs University class: OTHER briefSummary: This study aimed to evaluate the effects of kinesio taping on blood gas parameters, respiratory rate, heart rate, oxygen saturation, and pressure limits in preterm infants with RDS who are on NIV. It is hypothesized that the application of kinesio taping to the chest area of preterm infants may improve respiratory functions and oxygenation at the alveolar level, leading to decreased work of breathing, reduced respiratory rate, and improved neonatal stability by promoting respiratory mechanics and enhancing chest expansion. conditions: Preterm conditions: Premature conditions: Infant, Newborn, Diseases conditions: Respiratory Distress Syndrome conditions: Neonatal Respiratory Distress studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Kinesio-Taping Application primaryPurpose: TREATMENT masking: NONE count: 26 type: ACTUAL name: kinesiotaping application measure: Level of pH sex: ALL minimumAge: 1 Month maximumAge: 4 Months stdAges: CHILD facility: Nilay Çömük Balci city: Samsun state: Atakum zip: 55139 country: Turkey lat: 41.27976 lon: 36.3361 hasResults: False
nctId: NCT06285656 id: ASH-KG briefTitle: Femoral Blood Gas and Prediction of Postoperative Bleeding overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-10-01 date: 2024-10-03 date: 2024-02-29 date: 2024-02-29 name: Ankara City Hospital Bilkent class: OTHER briefSummary: Postoperative bleeding is still an important concern after major abdominal surgery. Postoperative bleeding is the most important determinant of morbidity and death. It results in longer hospital stays, the necessity for extra radiological tests, interventional radiology treatments, and the possibility of reoperation. Early detection of postoperative bleeding reduces morbidity and mortality with appropriate intervention.Simultaneous arterial and venous blood gas measurements can be used to quickly identify the degree of bleeding and the need for replacement in serious trauma patients brought to the emergency room.Lactate levels, venous oxygen saturation, and the differential in partial pressure of carbon dioxide between arterial and venous blood can all be used to indicate the requirement for replacement, as demonstrated in several studies. The purpose of this study is to evaluate lactate levels, venous oxygen saturation, and arterial-venous partial pressure of carbon dioxide difference in blood gas analysis in order to assess the severity of bleeding in patients undergoing major abdominal surgery as early as possible and perform replacement as soon as possible. conditions: Postoperative Hemorrhage conditions: Blood Transfusion studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED measure: Eritrocyte replacement measure: Postoperative Hemmorhagea sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06285643 id: ASK-PD5-CS201 briefTitle: A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) acronym: REGENERATE-PD overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2027-11-30 date: 2027-11-30 date: 2024-02-29 date: 2024-02-29 name: Asklepios Biopharmaceutical, Inc. class: INDUSTRY name: Bayer briefSummary: The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease. conditions: Parkinson Disease studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 87 type: ESTIMATED name: AAV2-GDNF Gene therapy name: Control Surgery measure: Motor symptoms-MDS-UPDRS parts 2 and 3 measure: PD Motor Diary Non-Motor symptoms-MDS-UPDRS part1 measure: PDQ39 Levodopa Equivalent Daily Dose measure: Change from baseline in the MDS-UPDRS parts 2 and 3, and the PD Motor Diary measure: Change from baseline in the MDS-UPDRS part 1 and PDQ-39 measure: Change in Levodopa equivalent daily dose sex: ALL minimumAge: 45 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06285630 id: Alba101 id: 2023-05299-01 type: OTHER domain: Ethix briefTitle: The Development and Health of the Intestinal Flora During the First Year of Life acronym: PREVENT overallStatus: ENROLLING_BY_INVITATION date: 2024-02-26 date: 2024-10-30 date: 2024-12-20 date: 2024-02-29 date: 2024-02-29 name: Alba Health AB class: INDUSTRY name: Universiteit Antwerpen name: Uppsala University name: Copenhagen Studies on Asthma in Childhood briefSummary: In this research study (PREVENT 1), Alba Health, in collaboration with academic institutions (Uppsala University, COPSAC and University of Antwerp) is investigating the association between the developing gut microbiota (collection of microbes present in the human gut) in the first year of life and lifestyle, wellbeing and health in a Swedish population. The study is the first of its kind in a Swedish population to collect and associate microbiome composition to an extensive family history and health questionnaire, stool colour and crying type, building on learnings from previous studies performed in other countries, such as the HELMI and COPSAC studies (HELMI - Finnish Health and Early Life Microbiota cohort from the University of Helsinki in Finland; COPSAC - Copenhagen Prospective Studies on Asthma in Childhood in Denmark).
The PREVENT 1 study is an observational research study led by Alba Health involving 300 families in Sweden with children between 0 and 12 months of age at the time of the study's start. After providing informed consent, the participating families will be asked to provide three stool samples from their child (the sample collection is not invasive and does not cause discomfort) and will be asked to answer questionnaires on lifestyle, well-being and family health. The participating families will not be asked to change their lifestyle beyond sample and data collection.
From the collected stool samples, we will extract microbial DNA and subject this to deep metagenomic sequence analysis. The study will only analyze microbial DNA, any human related material will be discarded. The stool samples will be destroyed within one month of sequencing (maximum 3 months from collection). The data will be stored according to GDPR and Swedish law, with informed consent in Sweden and with appropriate security measures. All research will be carried out in Sweden. conditions: Healthy conditions: Microbial Colonization studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED name: Observational, no intervation will be made measure: Microbiome composition of infants in variable age ranges measure: Is the composition associated with and gastrointestinal issues sex: ALL minimumAge: 3 Months maximumAge: 12 Months stdAges: CHILD facility: Alba Health AB city: Stockholm country: Sweden lat: 59.33258 lon: 18.0649 hasResults: False